keyword
MENU ▼
Read by QxMD icon Read
search

Relapsing MS

keyword
https://www.readbyqxmd.com/read/30118859/oxylipins-in-cerebrospinal-fluid-in-clinically-isolated-syndrome-and-relapsing-remitting-multiple-sclerosis
#1
Irene Håkansson, Sandra Gouveia-Figueira, Jan Ernerudh, Magnus Vrethem, Nazdar Ghafouri, Bijar Ghafouri, Malin Nording
Although oxylipins are involved in inflammation, data on these lipid mediators in multiple sclerosis are sparse. In this study, a panel of oxylipins were analysed with liquid chromatography tandem mass spectrometry in cerebrospinal fluid (CSF) from 41 treatment naïve patients with clinically isolated syndrome (CIS) or relapsing remitting MS (RRMS) and 22 healthy controls. CSF levels of 9-hydroxyoctadecadienoic acid (9-HODE) and 13-hydroxyoctadecadienoic acid (13-HODE) were significantly higher in patients than in healthy controls (9-HODE median 380 nM (interquartile range 330-450 nM) in patients and 290 nM (interquartile range 250-340 nM) in controls, 13-HODE median 930 nM (interquartile range 810-1080 nM) in patients and 690 nM (interquartile range 570-760 nM) in controls, p < 0...
August 14, 2018: Prostaglandins & Other Lipid Mediators
https://www.readbyqxmd.com/read/30117230/improvement-of-medical-judgements-by-numerical-training-in-patients-with-multiple-sclerosis
#2
Laura Zamarian, Margarete Delazer, Rainer Ehling, Marie-Theres Pertl, Gabriel Bsteh, Johanna Wenter, Susanne Glatzl, Christian Brenneis, Thomas Benke, Thomas Berger
BACKGROUND: People with multiple sclerosis (MS) have to face important decisions with regard to their medical treatment. OBJECTIVE: To evaluate whether a targeted cognitive training reduces framing effects and thus improves medical judgements. METHODS: This was a randomised, double-blind, cross-over study enrolling relapsing-remitting MS (RRMS) patients and healthy controls (HC). Participants were randomly assigned to training order A (first week: numerical training, second week: control training) or B (reverse order)...
August 17, 2018: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/30116116/feasibility-and-effects-of-structured-physical-exercise-interventions-in-adults-with-relapsing-remitting-multiple-sclerosis-a-pilot-study
#3
Elisabet Guillamó, Álvaro Cobo-Calvo, Guillermo R Oviedo, Noémie Travier, Juan Álamo, Oscar A Niño-Mendez, Antonio Martínez-Yelamos, Sergio Martínez-Yelamos, Casimiro Javierre
Multiple sclerosis (MS) is a chronic neurological disease which affects young adults at a time of maximum personal, professional and social growth. Recent guidelines on physical activity have established that exercise is an essential component of the clinical management of people with MS with mild or moderate degree of disability. The main purpose of this study was to test the feasibility and the effects of two different 40-week structured physical exercise interventions (a supervised high intensity interval training plus home exercise program and a self-applied home-based exercise program) on clinical evolution, psychological wellbeing, quality of life, fatigue, cardiorespiratory fitness, strength and balance of people with MS...
September 2018: Journal of Sports Science & Medicine
https://www.readbyqxmd.com/read/30114626/dysregulation-of-long-non-coding-rna-profile-in-peripheral-blood-of-multiple-sclerosis-patients
#4
Romina Dastmalchi, Soudeh Ghafouri-Fard, Mir Davood Omrani, Mehrdokht Mazdeh, Arezou Sayad, Mohammad Taheri
Multiple sclerosis (MS) is a chronic autoimmune disorder in which dysregulation or aberrant expressions of several immune-related genes have been noted. More recently, the participation of long non-coding RNAs (lncRNAs) in regulation of immune responses has been highlighted. In the present study, we evaluated expression levels of three lncRNAs named Nuclear Paraspeckle Assembly Transcript 1 (NEAT1), P21 associated ncRNA DNA damage activated (PANDA) and Taurine-up-regulated gene 1 (TUG1) in peripheral blood of 50 relapsing-remitting MS patients and 50 matched healthy subjects...
August 1, 2018: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/30114544/a-frontal-tumefactive-demyelinating-lesion-mimicking-glioblastoma-differentiated-by-methionine-positron-emission-tomography
#5
Shoji Yasuda, Hirohito Yano, Akio Kimura, Natsuko Suzui, Noriyuki Nakayama, Jun Shinoda, Toru Iwama
BACKGROUND: Tumefactive demyelinating lesion (TDL) is often reported as a rare variation of multiple sclerosis (MS). TDL is difficult to diagnose solely by magnetic resonance imaging (MRI) in patients with no history of MS. This is because the lesion often shows ring enhancement with perifocal brain edema on gadolinium MRI, thus mimicking glioblastoma multiforme (GBM). CASE DESCRIPTION: A 54-year-old healthy woman complained of headache 1 month before admission...
August 13, 2018: World Neurosurgery
https://www.readbyqxmd.com/read/30114292/orthologous-proteins-of-experimental-de-and-remyelination-are-differentially-regulated-in-the-csf-proteome-of-multiple-sclerosis-subtypes
#6
Nellie A Martin, Arkadiusz Nawrocki, Viktor Molnar, Maria L Elkjaer, Eva K Thygesen, Miklos Palkovits, Peter Acs, Tobias Sejbaek, Helle H Nielsen, Zoltan Hegedus, Finn Sellebjerg, Tihamer Molnar, Eudes G V Barbosa, Nicolas Alcaraz, Ferenc Gallyas, Asa F Svenningsen, Jan Baumbach, Hans Lassmann, Martin R Larsen, Zsolt Illes
OBJECTIVE: Here, we applied a multi-omics approach (i) to examine molecular pathways related to de- and remyelination in multiple sclerosis (MS) lesions; and (ii) to translate these findings to the CSF proteome in order to identify molecules that are differentially expressed among MS subtypes. METHODS: To relate differentially expressed genes in MS lesions to de- and remyelination, we compared transcriptome of MS lesions to transcriptome of cuprizone (CPZ)-induced de- and remyelination...
2018: PloS One
https://www.readbyqxmd.com/read/30113249/prognostic-value-of-cerebrospinal-fluid-neurofilament-light-chain-and-chitinase-3-like-1-in-newly-diagnosed-patients-with-multiple-sclerosis
#7
Finn Sellebjerg, Lydia Royen, Per Soelberg Sørensen, Annette Bang Oturai, Poul Erik Hyldgaard Jensen
BACKGROUND: Neurofilament light chain (NFL) and chitinase-3-like-1 (CHI3L1) concentrations in cerebrospinal fluid (CSF) may have prognostic value in clinically isolated syndromes (CIS) and relapsing-remitting multiple sclerosis (RRMS). OBJECTIVES: To compare the prognostic value of CSF concentrations of NFL and CHI3L1 in newly diagnosed CIS and RRMS patients. METHODS: NFL and CHI3L1 were measured in CSF in 177 newly diagnosed patients with CIS or RRMS who were followed clinically for a mean of 5...
August 16, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30109480/anti-jc-virus-antibody-index-changes-in-rituximab-treated-multiple-sclerosis-patients
#8
Ursela Baber, Andrew Bouley, Emily Egnor, Jacob A Sloane
Rituximab, a monoclonal antibody to CD20, is an effective treatment for relapsing remitting multiple sclerosis (MS) reducing relapse rate by at least 50% over time. Although the mechanism for this clinical benefit is unclear, rituximab depletes circulating B cells, which can perform antigen presentation and stimulation of T cells. Another anti-CD20 drug, ocrelizumab, has recently been FDA approved to treat both relapsing remitting and progressive forms of MS. While long-term effects of ocrelizumab use are essentially unknown, long-term use of rituximab has been associated with the development of progressive multifocal leukoencephalopathy (PML) at an incidence of approximately 1/25,000 in non-MS conditions...
August 14, 2018: Journal of Neurology
https://www.readbyqxmd.com/read/30105527/cladribine-tablets-a-review-in-relapsing-ms
#9
Emma D Deeks
Cladribine is a deoxyadenosine analogue prodrug that preferentially depletes lymphocytes, key cells underlying multiple sclerosis (MS) pathogenesis. Cladribine tablets (Mavenclad® ) represent the first short-course oral disease-modifying drug (DMD) for use in MS. The tablets, administered in two short courses 1 year apart, are indicated for the treatment of adults with highly active relapsing MS on the basis of data from pivotal clinical trials, including the phase 3 study CLARITY and its extension. A cumulative cladribine tablets dose of 3...
August 14, 2018: CNS Drugs
https://www.readbyqxmd.com/read/30105155/identifying-priority-outcomes-that-influence-selection-of-disease-modifying-therapies-in-ms
#10
Gregory S Day, Alexander Rae-Grant, Melissa J Armstrong, Tamara Pringsheim, Stacey S Cofield, Ruth Ann Marrie
Background: Persons with multiple sclerosis (MS) may now choose from a broad array of approved disease-modifying treatments (DMTs). The priority that patients and practitioners assign to specific clinical outcomes is likely to influence the MS DMT selection process. Methods: We invited 9,126 participants in the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry and 18 members of the American Academy of Neurology MS DMT guideline development panel to complete a brief survey prioritizing outcomes of importance to MS DMT selection...
June 2018: Neurology. Clinical Practice
https://www.readbyqxmd.com/read/30103975/predictors-of-relapse-and-disability-progression-in-ms-patients-who-discontinue-disease-modifying-therapy
#11
Ilya Kister, Tim Spelman, Francesco Patti, Pierre Duquette, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Pierre Grammond, Patrizia Sola, Diana Ferraro, Francois Grand'Maison, Raed Alroughani, Murat Terzi, Cavit Boz, Raymond Hupperts, Jeannette Lechner-Scott, Ludwig Kappos, Eugenio Pucci, Suzanne Hodgkinson, Claudio Solaro, Helmut Butzkueven
BACKGROUND: Discontinuation of disease-modifying therapies (DMTs) for MS is common. MSBase, a large global observational registry, affords a unique opportunity to investigate predictors of 'post-DMT' relapses and confirmed disability progression (CDP) in a diverse group of patients exposed to different DMTs. MATERIALS/METHODS: Main inclusion criteria: clinician-confirmed MS diagnosis (2010 McDonald criteria); age ≥ 18 at index DMT start; ≥12 months on index DMT prior to discontinuation; ≥24 months of follow-up post-discontinuation; did not restart DMT for ≥6 months...
August 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/30103962/diffusion-tensor-imaging-findings-in-the-multiple-sclerosis-patients-and-their-relationships-to-various-aspects-of-disability
#12
A Pokryszko-Dragan, A Banaszek, M Nowakowska-Kotas, K Jeżowska-Jurczyk, E Dziadkowiak, E Gruszka, M Zagrajek, M Bilińska, S Budrewicz, M Sąsiadek, J Bladowska
BACKGROUND: The aim of the study was to assess microstructural changes within strategic brain regions in multiple sclerosis (MS) patients, using diffusion tensor imaging (DTI), with regard to various aspects of disability. MATERIAL AND METHODS: The study comprised 50 patients with relapsing-remitting MS (37 women, 13 men, mean age 36.4 yrs) and 27 age- and sex-matched controls. Using DTI, fractional anisotropy (FA) and apparent diffusion coefficient (ADC) values were obtained within corpus callosum (CC), both thalami (TH) and middle cerebellar peduncles (MCP)...
August 15, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/30103751/metabolism-of-primaquine-in-normal-human-volunteers-investigation-of-phase-i-and-phase-ii-metabolites-from-plasma-and-urine-using-ultra-high-performance-liquid-chromatography-quadrupole-time-of-flight-mass-spectrometry
#13
Bharathi Avula, Babu L Tekwani, Narayan D Chaurasiya, Pius Fasinu, N P Dhammika Nanayakkara, H M T Bhandara Herath, Yan-Hong Wang, Ji-Yeong Bae, Shabana I Khan, Mahmoud A Elsohly, James D McChesney, Peter A Zimmerman, Ikhlas A Khan, Larry A Walker
BACKGROUND: Primaquine (PQ), an 8-aminoquinoline, is the only drug approved by the United States Food and Drug Administration for radical cure and prevention of relapse in Plasmodium vivax infections. Knowledge of the metabolism of PQ is critical for understanding the therapeutic efficacy and hemolytic toxicity of this drug. Recent in vitro studies with primary human hepatocytes have been useful for developing the ultra high-performance liquid chromatography coupled with high-resolution mass spectrometric (UHPLC-QToF-MS) methods for simultaneous determination of PQ and its metabolites generated through phase I and phase II pathways for drug metabolism...
August 13, 2018: Malaria Journal
https://www.readbyqxmd.com/read/30102003/spinal-cord-atrophy-in-multiple-sclerosis-a-systematic-review-and-meta-analysis
#14
Courtney Casserly, Estelle E Seyman, Paula Alcaide-Leon, Melanie Guenette, Carrie Lyons, Stephanie Sankar, Anton Svendrovski, Stefan Baral, Jiwon Oh
BACKGROUND AND PURPOSE: Spinal cord atrophy (SCA) is an important emerging outcome measure in multiple sclerosis (MS); however, there is limited consensus on the magnitude and rate of atrophy. The objective of this study was to synthesize the available data on measures of SCA in MS. METHODS: Using published guidelines, relevant literature databases were searched between 1977 and 2017 for case-control or cohort studies reporting a quantitative measure of SCA in MS patients...
August 13, 2018: Journal of Neuroimaging: Official Journal of the American Society of Neuroimaging
https://www.readbyqxmd.com/read/30099203/a-contemporary-study-of-mortality-in-the-multiple-sclerosis-population-of-south-east-wales
#15
Katharine Harding, Valerie Anderson, Owain Williams, Mark Willis, Sara Butterworth, Emma Tallantyre, Fady Joseph, Mark Wardle, Trevor Pickersgill, Neil Robertson
BACKGROUND: Mortality studies in multiple sclerosis (MS) are valuable to identify changing disease patterns and inform clinical management. This study examines mortality in a British MS cohort. METHODS: Patients were selected from the southeast Wales MS registry. Hazard of death was analysed using Cox proportional hazards regression, adjusted for onset age, annualised relapse rate, initial disease course, time to EDSS 4.0, sex, socioeconomic status, and onset year...
August 2, 2018: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/30096684/factors-associated-with-perceived-need-for-mental-health-care-in-multiple-sclerosis
#16
Justine Orr, Charles N Bernstein, Lesley A Graff, Scott B Patten, James M Bolton, Jitender Sareen, James J Marriott, John D Fisk, Ruth Ann Marrie
BACKGROUND: Within the multiple sclerosis (MS) population, depression and anxiety are highly prevalent comorbidities that are associated with adverse outcomes such as diminished quality of life and disability progression. In the general population, many people who do not meet formal diagnostic criteria for depression or anxiety disorders still identify a need for mental health care. Limited data are available regarding the perceived need for mental health care among persons with MS. OBJECTIVE: We aimed to determine factors associated with a perceived need for mental health care in the MS population...
July 29, 2018: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/30096568/consensus-recommendations-for-the-diagnosis-and-treatment-of-primary-progressive-multiple-sclerosis-in-latin-america
#17
REVIEW
Edgardo Cristiano, Juan Ignacio Rojas, Patricio Abad, Tarso Adoni, Jorge Barahona, Jefferson Becker, Adriana Carrá, José Flores, Manuel Fruns, Nora Fernández Liguori, Orlando Garcea, Juan García Bónito, Diego Giunta, Fernando Gracia, Fernando Hamuy, Miguel A Macias Islas, Cárlos Navas, Liliana Ordoñez Boschetti, Liliana Patrucco, Douglas K Sato, Jorge Correale
Despite the availability of a large amount of information regarding the management and care of relapsing remitting multiple sclerosis (RRMS) patients, there is scant information about recommendations on how to care for primary progressive MS (PPMS) patients. The objective of this study was to review how PPMS patients should be assessed and cared for in Latin America (LATAM). METHODS: A panel of neurology experts from LATAM dedicated to the diagnosis and care of MS patients gathered virtually during 2017 and 2018 to carry out a consensus recommendation on the diagnosis and treatment of PPMS patients in LATAM...
July 31, 2018: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/30090125/early-onset-multiple-sclerosis-reports-of-300-patients-from-iran
#18
Fateme Omrani, Mohamamad Ali Sahraian, Amirreza Azim Saeen, Zahra Omrani, Ghazal Hayeri
Background: The epidemiologic data on demographic features of early-onset multiple sclerosis (EOMS) are rare in the Middle East, and no previous study has explored it. We aim to perform a neuroepidemiologic analysis to emphasize on the demographic features of EOMS in Tehran, Iran, during 2005-2015. Materials and Methods: Our study was performed in Tehran, Iran; the research included patients with EOMS who had experienced their first symptoms before the age of 18 years and those who were referred to Iranian Multiple Sclerosis Society in Tehran during 2005-2015...
April 2018: Journal of Pediatric Neurosciences
https://www.readbyqxmd.com/read/30090102/immunophenotype-and-transcriptome-profile-of-patients-with-multiple-sclerosis-treated-with-fingolimod-setting-up-a-model-for-prediction-of-response-in-a-2-year-translational-study
#19
Irene Moreno-Torres, Coral González-García, Marco Marconi, Aranzazu García-Grande, Luis Rodríguez-Esparragoza, Víctor Elvira, Elvira Ramil, Lucía Campos-Ruíz, Ruth García-Hernández, Fátima Al-Shahrour, Coral Fustero-Torre, Alicia Sánchez-Sanz, Antonio García-Merino, Antonio José Sánchez López
Background: Fingolimod is a functional sphingosine-1-phosphate antagonist approved for the treatment of multiple sclerosis (MS). Fingolimod affects lymphocyte subpopulations and regulates gene expression in the lymphocyte transcriptome. Translational studies are necessary to identify cellular and molecular biomarkers that might be used to predict the clinical response to the drug. In MS patients, we aimed to clarify the differential effects of fingolimod on T, B, and natural killer (NK) cell subsets and to identify differentially expressed genes in responders and non-responders (NRs) to treatment...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/30086721/evaluation-of-patients-with-relapsing-remitting-multiple-sclerosis-using-tract-based-spatial-statistics-analysis-diffusion-kurtosis-imaging
#20
Hai Qing Li, Bo Yin, Chao Quan, Dao Ying Geng, Hai Yu, Yi Fang Bao, Jun Liu, Yu Xin Li
BACKGROUND: Diffusion kurtosis imaging (DKI) has the potential to provide microstructural insights into myelin and axonal pathology with additional kurtosis parameters. To our knowledge, few studies are available in the current literature using DKI by tract-based spatial statistics (TBSS) analysis in patients with multiple sclerosis (MS). The aim of this study is to assess the performance of commonly used parameters derived from DKI and diffusion tensor imaging (DTI) in detecting microstructural changes and associated pathology in relapsing remitting MS (RRMS)...
August 7, 2018: BMC Neurology
keyword
keyword
161175
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"